Abstracts Archive - Page 1804 of 2607 - ACR Meeting Abstracts

Abstract Number: 3079 • 2016 ACR/ARHP Annual Meeting
The Characteristic Features of the Patients with Deficiency of Adenosine Deaminase 2 (DADA2)
Abdulsamet Erden¹, Ezgi Deniz Batu², Ekim Z. Taskiran³, Hafize Emine Sonmez², Alper Sari¹, Berkan Armagan¹, Levent Kilic¹, Zehra Serap Arıcı⁴, Yelda Bilginer⁵, Ali Akdogan¹, Omer Karadag¹, Umut Kalyoncu¹ and Seza Ozen^6,7, ¹Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ²Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ³Department of Medical Genetics, Hacettepe University Faculty of Medicine, ANKARA, Turkey, ⁴Departments of Pediatric Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁵Departments of Pediatric Nephrology and Rheumatology, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁶Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁷Department of Pediatrics, Division of Rheumatology, Hacettepe University Faculty of Medicine, ANKARA, Turkey
Background/Purpose: Deficiency of adenosine deaminase 2 (DADA2) is an autosomal recessive autoinflammatory disease resulting from a loss-of-function mutation in Cat Eye Syndrome Chromosome Region Candidate…
Abstract Number: 3080 • 2016 ACR/ARHP Annual Meeting
Rheumatologic Consequences of Immunotherapy to Treat Malignancies: The Tip of an Iceberg
Laura Cappelli¹, Anna Kristina Gutierrez², Alan N. Baer², Jemima Albayda³, Rebecca L. Manno², Uzma Haque³, Ami A. Shah³, Evan Lipson⁴, Karen Bleich⁵, Julie Brahmer⁴, Patrick Forde⁴, Dung Le⁶, Jarushka Naidoo⁴ and Clifton Bingham III⁷, ¹Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Radiology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Johns Hopkins University, Baltimore, MD
Rheumatologic Consequences of Immunotherapy to Treat Malignancies: The Tip of an Iceberg Background/Purpose: Immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed…
Abstract Number: 3081 • 2016 ACR/ARHP Annual Meeting
Prognostic Factors of Death in a Cohort of 116 Adults with Hemophagocytic Syndrome: Impact of Underlying Disease and Laboratory Parameters
Pilar Brito-Zerón¹, Pedro Moral Moral², Belchin Kostov³, Luis Caminal-Montero⁴, Guadalupe Fraile⁵, Eva Fonseca⁶, Patricia Pérez Guerrero⁷, Angel Robles⁸, Antonio J. Chamorro⁹, María Andrés Calvo¹⁰, José Ramón Larrañaga¹¹, Maria José Forner¹², Mónica Rodriguez Carballeira¹³, Manuel Ruiz Muñoz¹⁴, Roberto Hurtado García¹⁵, Luis Fernando Viejo Llorente¹⁶, Sergio Prieto-González¹⁷, Pedro Castro¹⁸, Aleida Martínez Zapico⁴, María Vaquero Herrero⁹, Angela Ruiz de Temiño de la Peña¹⁰, Soledad Retamozo^1,19, Manuel Ramos-Casals²⁰ and REGHEM-GEAS-SEMI Spanish Cohort, ¹Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Barcelona, Spain, ²Department of Internal Medicine, Hospital La Fé, Valencia, Valencia, Spain, ³Research Group in Primary Care, IDIBAPS, ABS Les Corts, CAPSE, Barcelona, Spain, ⁴Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Spain, ⁵Department of Internal Medicine, Hospital Ramón y Cajal, Madrid, Spain, Madrid, Spain, ⁶Department of Internal Medicine, Hospital de Cabueñes, Gijón, Gijón, Spain, ⁷Department of Internal Medicine, Hospital Universitario Puerta del Mar, Cádiz, Cadiz, Spain, ⁸Department of Internal Medicine, Hospital La Paz, Madrid, Madrid, Spain, ⁹Department of Internal Medicine, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain, ¹⁰Department of Internal Medicine, Hospital Rio Hortega, Valladolid, Valladolid, Spain, ¹¹Department of Internal Medicine, Hospital Xeral, Vigo, Vigo, Spain, ¹²Department of Internal Medicine, Hospital Clínico de Valencia, Valencia, Spain, ¹³Department of Internal Medicine, Hospital Mutua de Terrasa, Terrasa, Spain, ¹⁴Department of Internal Medicine, Hospital Universitario Fundacion Alcorcón, Madrid, Spain, ¹⁵Department of Internal Medicine, Hospital Vega Baja, Orihuela, Orihuela, Spain, ¹⁶Department of Internal Medicine, Hospital Virgen de la Salud, Toledo, Toledo, Spain, ¹⁷Department of Autoimmune Diseases, ICMiD, Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁸Medical Intensive Care Unit, ICMiD, Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁹Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, ²⁰Laboratory of Systemic Autoimmune Diseases “Josep Font”, CELLEX, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Department of Systemic Autoimmune Diseases, ICMID, Hospital Clinic, Barcelona, Spain, Barcelona, Spain
Background/Purpose: To analyze the potential use of the main features at diagnosis (epidemiological, clinical, laboratory) as prognostic factors and to estimate the risk of death…
Abstract Number: 3082 • 2016 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome Is Identified By Coagulopathy, Hyperferritinemia, Fever, and Cytopenia in Hospitalized Patients, Resulting in Poor Outcome
Bita Shakoory¹, Negin Mohtasham², Matthew Mullen³, Richard Amdur⁴ and W. Winn Chatham⁵, ¹None, MCLEAN, VA, ²Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran (Islamic Republic of), ³Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Surgery, George Washington University, Washington, DC, ⁵Medicine/Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Macrophage activation syndrome (MAS) constitutes over 5% of multi-organ dysfunction syndrome in adults, leading to 60-70% mortality without early treatment. H-Score, the only validated…
Abstract Number: 3083 • 2016 ACR/ARHP Annual Meeting
Utility of Patient-Reported Outcomes Measurement Information System (PROMIS) 29 Short Form for Understanding Interplay Between Patient-Reported Outcome Measures and Physician Driven Disease Activity Measures
Yong Gil Hwang¹, Juan (June) Feng², Heather Eng², Jason Lyons², Anthony Fabio² and Larry W. Moreland¹, ¹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology, University of Pittsburgh, School of Public Health, Pittsburgh, PA
Background/Purpose: Discordance between patient and physician assessment of rheumatoid arthritis (RA) disease activity strongly associates with pain scores. Patient-reported outcomes measurement information system (PROMIS) 29…
Abstract Number: 3084 • 2016 ACR/ARHP Annual Meeting
The Impact of Mental Health on Indicators of Disease Severity Among Patients with Inflammatory Arthritis: A Cross-Sectional and Longitudinal Investigation
Renee El-Gabalawy¹, Mathew Bernstein², Cory Mackenzie³, Jitender Sareen⁴ and Carol Hitchon⁵, ¹Clinical Health Psychology and Anesthesia & Perioperative Medicine, University of Manitoba, Winnipeg, MB, Canada, ²Clinical Psychology, University of Manitoba, Winnipeg, MB, Canada, ³Psychology, University of Manitoba, Winnipeg, MB, Canada, ⁴Psychiatry, University of Manitoba, Winnipeg, MB, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Rheumatoid arthritis, is the leading cause of disability and chronic pain. Psychiatric disorders such as depression and anxiety adversely impact reported pain and may…
Abstract Number: 3085 • 2016 ACR/ARHP Annual Meeting
Do Depression and Anxiety Reduce the Chance of Remission in Rheumatoid Arthritis and Psoriatic Arthritis?
Brigitte Michelsen^1,2, Karen M Fagerli¹, Elisabeth Lie¹, Hilde Berner Hammer³, Glenn Haugeberg^4,5, Eirik K Kristianslund¹ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Dept. of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Dept. of Rheumatology, Martina Hansens Hospital, Bærum, Norway, ⁵Dept. of Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: Depression and anxiety are reported to predict poorer treatment outcomes in rheumatoid arthritis (RA).1 Whether this can be confirmed in larger, prospective studies as…
Abstract Number: 3086 • 2016 ACR/ARHP Annual Meeting
Changing Patterns over Time in Opiate Use in U.S. Rheumatoid Arthritis Patients
Jeffrey Curtis¹, Fenglong Xie², Kenneth Saag³, Lang Chen², Timothy Beukelman⁴, Melissa Mannion⁵ and Huifeng Yun⁶, ¹Division Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Pediatric Rheumatology, University of Alabama-Birmingham, Birmingham, AL, ⁵Pediatrics, University of Alabama at Birmingham, Birmingham, AL, ⁶Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Background/Purpose: Opiate use has come under increasing scrutiny related both to over-use and under-use. The patterns of opiate use over time in a population-based cohort…
Abstract Number: 3087 • 2016 ACR/ARHP Annual Meeting
Association of Weight Loss with Improved Disease Activity in Patients with Rheumatoid Arthritis
David J. Kreps^1,2, Florencia Halperin³, Sonali P. Desai³, Zhi Zhang³, Elena Losina³, Elizabeth W. Karlson¹, Bonnie L. Bermas¹ and Jeffrey A. Sparks⁴, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Boston University, Boston, MA, ³Division of Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose : Obesity has been associated with worsened RA outcomes and increased disease activity. However, few longitudinal studies have investigated whether weight loss might improve…
Abstract Number: 3088 • 2016 ACR/ARHP Annual Meeting
Predictors of Non-Adherence with Anti-Rheumatic Medication in Rheumatoid Arthritis Patients: Data from a Rheumatoid Arthritis Cohort
Vandana Ahluwalia¹, Mohammad Movahedi^2,3, Emmanouil Rampakakis², Angela Cesta³, Xiuying Li³, John S. Sampalis⁴ and Claire Bombardier⁵, ¹Brampton Civic Hospital, Brampton, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Toronto, Toronto, ON, Canada
Background/Purpose: Despite the availability of safe and effective treatments and the establishment of treatment guidelines, real-world effectiveness remains suboptimal largely due to low patient adherence…
Abstract Number: 3089 • 2016 ACR/ARHP Annual Meeting
Predicting the Response to TNF Inhibition or B Cell Depletion Therapy from Peripheral Whole Blood Gene Expression Profiles in Patients with Rheumatoid Arthritis
Duncan Porter¹, C. S. Goodyear², J. S. Nijjar¹, Martina Messow³, Stefan Siebert¹, Manikhandan Mudaliar⁴ and Iain B. McInnes⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Robertson Centre for Biostatistics, Institute of Health and Wellbeing, University of Glasgow, Glasgow, United Kingdom, ⁴Glasgow Polyomics Facility, University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, Great Britain
Background/Purpose: The ORBIT study demonstrated that rituximab is non-inferior to a TNFi-first strategy in biologic naive, sero-positive patients with active RA over 12 months (Lancet…
Abstract Number: 3090 • 2016 ACR/ARHP Annual Meeting
Inflammation Detected with Modern Sensitive MRI Analysis Demonstrates That Therapeutic Response As Early As One Month Predicts 12-Month Radiographic Progression: Data from a Study Using Tofacitinib and Methotrexate in Early RA
Philip G. Conaghan¹, Michael A Bowes², Mikkel Østergaard³, Gwenael Guillard², Douglass Chapman⁴, Amy Stein⁵, John Andrews⁴, Zhiyong Xie⁶, Andrew Koenig⁷, Koshika Soma⁴ and Bethanie Wilkinson⁶, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ²Imorphics Ltd, Manchester, United Kingdom, ³Copenhagen Center for Arthritis Research, Copenhagen, Denmark, ⁴Pfizer Inc, New York, NY, ⁵Biostatistics, Quintiles, Morrisville, NC, ⁶Pfizer Inc, Groton, CT, ⁷Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A novel automated quantification method for RA MRI-detected pathology using statistical shape…
Abstract Number: 3091 • 2016 ACR/ARHP Annual Meeting
Effect of Sarilumab on Circulating Biomarkers of Bone and Joint Destruction in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate
Cem Gabay¹, Jérôme Msihid², Nikki Daskalakis³, Neil Graham⁴, Anne Barbot⁵, Moshe Zilberstein³ and Anita Boyapati⁴, ¹University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland, ²Sanofi, Chilly-Mazarin, France, Chilly-Mazarin, NJ, France, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Sanofi, Chilly-Mazarin, France, Chilly-Mazarin, France
Background/Purpose: Patients with RA develop bone and joint damage due to chronic inflammation that is mediated by a destructive synovial pannus.1 The pannus is composed…
Abstract Number: 3092 • 2016 ACR/ARHP Annual Meeting
Predictive Factors for Better Outcome of Switching of Biologics for Patients with Rheumatoid Arthritis in Daily Clinical Practice
Kazuyoshi Saito¹, Kazuhisa Nakano², Shingo Nakayamada³, Satoshi Kubo⁴, Ippei Miyagawa¹, Shigeru Iwata⁵ and Yoshiya Tanaka⁶, ¹University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁴The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁵First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ⁶University of Occupational and Environmental Health, Kitakyushu, Japan
Background/Purpose: Eight biologics have been approved for rheumatoid arthritis (RA) in Japan. However, little is known regarding what to do when patients have an inadequate…
Abstract Number: 3093 • 2016 ACR/ARHP Annual Meeting
Comparison of Changes in Cardiovascular Risk-Associated Biomarkers in RA Patients Treated with Anti-TNF or Other Biological Agents: A Metabolic Study from a Randomized Trial
Alexandre Virone¹, Jean-Philippe Bastard², Soraya Fellahi², Jacqueline Capeau², Stéphanie Rouanet³, Jean Sibilia⁴, Philippe Ravaud⁵, Francis Berenbaum⁶, Jacques-Eric Gottenberg⁷ and Jeremie Sellam⁶, ¹Rheumatology, Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ²APHP Hôpital Tenon, Sorbonne Universités, UPMC Univ Paris-6, Inserm UMR_S938, ICAN, DHU i2B, Paris, France, ³StatEthic, Levallois-Perret, France, ⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁵Hôpital Hôtel Dieu, Paris, France, ⁶Rheumatology dept, APHP St-Antoine hospital, Univ Paris 06, Paris, France, Paris, France, ⁷Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Considering the increased cardiovascular risk in RA patients and the influence of biologics, especially tocilizumab (TCZ) on the lipid profile, we aimed to investigate…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].